Market Cap 32.66M
Revenue (ttm) 20.60M
Net Income (ttm) -8.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -41.80%
Debt to Equity Ratio 0.00
Volume 422,800
Avg Vol 595,016
Day's Range N/A - N/A
Shares Out 44.66M
Stochastic %K 63%
Beta 1.12
Analysts Strong Sell
Price Target $4.19

Company Profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automati...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 201 884 5485
Address:
1 Evertrust Plaza, 13th Floor, Jersey City, United States
SnapCrackleStop
SnapCrackleStop May. 24 at 2:07 PM
$SCYX Yesterday is a memory or maybe a nightmare with a $406MM stockholders deficit. Yet, Tomorrow is tomorrow. A new day is dawning. $$$
1 · Reply
dthmich624
dthmich624 May. 23 at 9:01 PM
$SCYX 1:10 in 2020 and now 1:8 in 2026. This company is a shareholder nightmare. At least the end may be near for us long-term investors. Such promise, so little concern for retail schmucks like me and many others. Happy investing! Many thanks to those who paid the ultimate price for our freedoms - Happy Memorial Day! Your sacrifices are not forgotten.
0 · Reply
pantarei
pantarei May. 23 at 11:49 AM
0 · Reply
intheriver
intheriver May. 23 at 3:48 AM
$SCYX after market price of .624 = 4.99 post r/s. After market on a Friday. Shocker. Hopefully some good news is on the horizon. 😂 🤞 My last post here. Good luck, everyone.
1 · Reply
topstockalerts
topstockalerts May. 22 at 11:34 PM
Scynexis Inc announced a 1-for-8 reverse stock split effective May 29, 2026, aimed at regaining compliance with Nasdaq minimum bid price requirements. The split was approved by shareholders at a special meeting on May 19, 2026, with final terms set by the Board. Trading on a split-adjusted basis will begin on June 1, 2026 under the existing ticker, with a new CUSIP number. Each 8 outstanding shares will be consolidated into 1, reducing shares outstanding from ~79.5M to ~9.9M and authorized shares from 150M to 18.75M, without changing par value. Fractional shares will not be issued; affected holders will receive cash payments instead. Outstanding equity instruments (options, RSUs, warrants) will be proportionally adjusted, with corresponding increases in exercise prices. Equiniti Trust Company will act as exchange agent, and brokerage-held positions will be adjusted automatically. $SCYX
0 · Reply
Aurum81
Aurum81 May. 22 at 8:46 PM
$SCYX This really wasn't unexpected anymore—let's wait for BREXAFEMME news after the R/S, and the price will start moving up again
1 · Reply
LemuelPitkin
LemuelPitkin May. 22 at 8:17 PM
1 · Reply
intheriver
intheriver May. 22 at 1:12 PM
$SCYX a “French_Vibe” guy comes on this chat and tries to play a game of semantics, which was a complete waste of time and was to somehow undermine my points. SCYX calls itself a biotech and has a business model very similar to other biotechs. I’m tired of the crap. I clap back. There are no participation trophies here, we should all be focused on making money. Someone comes after me with some BS, and decides they are going to dig into some trivial point, that’s fine. But that’s exactly how I’ll treat their points. I don’t care if they whine and start calling people trolls for the BS they started. 👏 👏 - tired of the BS!! Fire the management!!
0 · Reply
intheriver
intheriver May. 21 at 10:49 PM
$SCYX someone came on this board wanting to seem informed, claiming SCYX is not a biotech. How misinformed does one have to be? Literally one of the strangest things I’ve seen since being here and researching companies like this. FROM SCYX MOST RECENT 10q: “SCYNEXIS, Inc. ("SCYNEXIS" or the “Company”) is a clinical-stage biotech company….” Don’t tell me, bud, tell SCYX. 🤡
0 · Reply
intheriver
intheriver May. 21 at 6:25 PM
$SCYX I’m fairly confident the R/S will be closer to 1 for 10. The goal is to provide clearance over $5. At this point, they should just do 10.
1 · Reply
Latest News on SCYX
Scynexis announces 1-for-8 reverse stock split

2026-05-22T20:21:28.000Z - 2 days ago

Scynexis announces 1-for-8 reverse stock split


SCYNEXIS Announces One-for-Eight Reverse Stock Split

May 22, 2026, 4:15 PM EDT - 2 days ago

SCYNEXIS Announces One-for-Eight Reverse Stock Split


SCYNEXIS Transcript: EGM 2026

May 19, 2026, 9:30 AM EDT - 5 days ago

SCYNEXIS Transcript: EGM 2026


Scynexis reports Q1 EPS (42c), consensus (12c)

2026-05-11T23:59:18.000Z - 13 days ago

Scynexis reports Q1 EPS (42c), consensus (12c)


SCYNEXIS Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 13 days ago

SCYNEXIS Quarterly report: Q1 2026


SCYNEXIS Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 13 days ago

SCYNEXIS Earnings release: Q1 2026


Scynexis files to sell 87M shares of common stock for holders

2026-05-01T20:05:19.000Z - 23 days ago

Scynexis files to sell 87M shares of common stock for holders


SCYNEXIS Registration statement: Registration filing

May 1, 2026, 8:00 AM EDT - 23 days ago

SCYNEXIS Registration statement: Registration filing


SCYNEXIS Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 24 days ago

SCYNEXIS Proxy statement: Proxy filing


SCYNEXIS Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 24 days ago

SCYNEXIS Proxy statement: Proxy filing


SCYNEXIS Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 27 days ago

SCYNEXIS Proxy statement: Proxy filing


SCYNEXIS Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 weeks ago

SCYNEXIS Proxy statement: Proxy filing


SCYNEXIS Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 5 weeks ago

SCYNEXIS Proxy statement: Proxy filing


SCYNEXIS Transcript: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 7 weeks ago

SCYNEXIS Transcript: M&A announcement


SCYNEXIS Press release: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 7 weeks ago

SCYNEXIS Press release: M&A announcement


SCYNEXIS Slides: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 7 weeks ago

SCYNEXIS Slides: M&A announcement


Poxel announces sale of PXL770 to Scynexis for up to $196M

2026-03-31T11:20:57.000Z - 7 weeks ago

Poxel announces sale of PXL770 to Scynexis for up to $196M


Scynexis announces $40M private placement

2026-03-31T10:50:10.000Z - 7 weeks ago

Scynexis announces $40M private placement


SCYNEXIS Announces $40.0 Million Private Placement

Mar 31, 2026, 6:45 AM EDT - 7 weeks ago

SCYNEXIS Announces $40.0 Million Private Placement


SCYNEXIS Earnings release: Q4 2025

Mar 4, 2026, 7:00 AM EST - 2 months ago

SCYNEXIS Earnings release: Q4 2025


SCYNEXIS Annual report: Q4 2025

Mar 4, 2026, 7:00 AM EST - 2 months ago

SCYNEXIS Annual report: Q4 2025


Cero Therapeutics appoints Eric Francois to board of directors

2026-02-17T13:20:59.000Z - 3 months ago

Cero Therapeutics appoints Eric Francois to board of directors


Scynexis announces presentation highlighting data from SCY-247

2026-01-28T13:25:56.000Z - 4 months ago

Scynexis announces presentation highlighting data from SCY-247


Scynexis completes transfer of BREXAFEMME NDA to GSK

2025-11-19T12:11:19.000Z - 6 months ago

Scynexis completes transfer of BREXAFEMME NDA to GSK

GSK


Scynexis reports Q3 EPS (17c), consensus (20c)

2025-11-05T23:00:31.000Z - 7 months ago

Scynexis reports Q3 EPS (17c), consensus (20c)


SCYNEXIS Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 7 months ago

SCYNEXIS Earnings release: Q3 2025


SCYNEXIS Quarterly report: Q3 2025

Nov 5, 2025, 4:00 PM EST - 7 months ago

SCYNEXIS Quarterly report: Q3 2025


SCYNEXIS Slides: investor presentation

Nov 5, 2025, 7:00 AM EST - 7 months ago

SCYNEXIS Slides: investor presentation


Scynexis price target lowered to $3 from $4 at Guggenheim

2025-10-28T11:41:34.000Z - 7 months ago

Scynexis price target lowered to $3 from $4 at Guggenheim

GSK


Scynexis announces presentations highlighting data on SCY-247

2025-09-04T12:40:22.000Z - 9 months ago

Scynexis announces presentations highlighting data on SCY-247


Scynexis reports Q2 EPS (14c), consensus (19c)

2025-08-13T20:45:47.000Z - 10 months ago

Scynexis reports Q2 EPS (14c), consensus (19c)


SCYNEXIS Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 10 months ago

SCYNEXIS Earnings release: Q2 2025


SCYNEXIS Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 10 months ago

SCYNEXIS Quarterly report: Q2 2025


Scynexis resumes patient dosing in Phase 3 MARIO study

2025-05-28T12:35:49.000Z - 1 year ago

Scynexis resumes patient dosing in Phase 3 MARIO study

GSK


SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025, 8:30 AM EDT - 1 year ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study


SCYNEXIS Earnings release: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

SCYNEXIS Earnings release: Q1 2025


SCYNEXIS Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

SCYNEXIS Quarterly report: Q1 2025


SCYNEXIS Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

SCYNEXIS Proxy statement: Proxy Filing


SCYNEXIS Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

SCYNEXIS Proxy statement: Proxy Filing


SCYNEXIS Annual report: Q4 2024

Mar 12, 2025, 5:00 PM EDT - 1 year ago

SCYNEXIS Annual report: Q4 2024


SCYNEXIS Earnings release: Q4 2024

Mar 12, 2025, 5:00 PM EDT - 1 year ago

SCYNEXIS Earnings release: Q4 2024


SCYNEXIS Quarterly report: Q3 2024

Oct 18, 2024, 4:00 PM EDT - 1 year ago

SCYNEXIS Quarterly report: Q3 2024


SCYNEXIS Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 1 year ago

SCYNEXIS Quarterly report: Q2 2024


SCYNEXIS Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 1 year ago

SCYNEXIS Earnings release: Q2 2024


SCYNEXIS Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Quarterly report: Q1 2024


SCYNEXIS Earnings release: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Earnings release: Q1 2024


SCYNEXIS Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

SCYNEXIS Proxy statement: Proxy Filing


SCYNEXIS Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

SCYNEXIS Proxy statement: Proxy Filing


SCYNEXIS Earnings release: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Earnings release: Q4 2023


SCYNEXIS Annual report: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Annual report: Q4 2023


SnapCrackleStop
SnapCrackleStop May. 24 at 2:07 PM
$SCYX Yesterday is a memory or maybe a nightmare with a $406MM stockholders deficit. Yet, Tomorrow is tomorrow. A new day is dawning. $$$
1 · Reply
dthmich624
dthmich624 May. 23 at 9:01 PM
$SCYX 1:10 in 2020 and now 1:8 in 2026. This company is a shareholder nightmare. At least the end may be near for us long-term investors. Such promise, so little concern for retail schmucks like me and many others. Happy investing! Many thanks to those who paid the ultimate price for our freedoms - Happy Memorial Day! Your sacrifices are not forgotten.
0 · Reply
pantarei
pantarei May. 23 at 11:49 AM
0 · Reply
intheriver
intheriver May. 23 at 3:48 AM
$SCYX after market price of .624 = 4.99 post r/s. After market on a Friday. Shocker. Hopefully some good news is on the horizon. 😂 🤞 My last post here. Good luck, everyone.
1 · Reply
topstockalerts
topstockalerts May. 22 at 11:34 PM
Scynexis Inc announced a 1-for-8 reverse stock split effective May 29, 2026, aimed at regaining compliance with Nasdaq minimum bid price requirements. The split was approved by shareholders at a special meeting on May 19, 2026, with final terms set by the Board. Trading on a split-adjusted basis will begin on June 1, 2026 under the existing ticker, with a new CUSIP number. Each 8 outstanding shares will be consolidated into 1, reducing shares outstanding from ~79.5M to ~9.9M and authorized shares from 150M to 18.75M, without changing par value. Fractional shares will not be issued; affected holders will receive cash payments instead. Outstanding equity instruments (options, RSUs, warrants) will be proportionally adjusted, with corresponding increases in exercise prices. Equiniti Trust Company will act as exchange agent, and brokerage-held positions will be adjusted automatically. $SCYX
0 · Reply
Aurum81
Aurum81 May. 22 at 8:46 PM
$SCYX This really wasn't unexpected anymore—let's wait for BREXAFEMME news after the R/S, and the price will start moving up again
1 · Reply
LemuelPitkin
LemuelPitkin May. 22 at 8:17 PM
1 · Reply
intheriver
intheriver May. 22 at 1:12 PM
$SCYX a “French_Vibe” guy comes on this chat and tries to play a game of semantics, which was a complete waste of time and was to somehow undermine my points. SCYX calls itself a biotech and has a business model very similar to other biotechs. I’m tired of the crap. I clap back. There are no participation trophies here, we should all be focused on making money. Someone comes after me with some BS, and decides they are going to dig into some trivial point, that’s fine. But that’s exactly how I’ll treat their points. I don’t care if they whine and start calling people trolls for the BS they started. 👏 👏 - tired of the BS!! Fire the management!!
0 · Reply
intheriver
intheriver May. 21 at 10:49 PM
$SCYX someone came on this board wanting to seem informed, claiming SCYX is not a biotech. How misinformed does one have to be? Literally one of the strangest things I’ve seen since being here and researching companies like this. FROM SCYX MOST RECENT 10q: “SCYNEXIS, Inc. ("SCYNEXIS" or the “Company”) is a clinical-stage biotech company….” Don’t tell me, bud, tell SCYX. 🤡
0 · Reply
intheriver
intheriver May. 21 at 6:25 PM
$SCYX I’m fairly confident the R/S will be closer to 1 for 10. The goal is to provide clearance over $5. At this point, they should just do 10.
1 · Reply
intheriver
intheriver May. 21 at 6:21 PM
$SCYX baby BIOs are literally the hardest place to make money. It’s based on a gamble that a company will have a successful product. And SCYX has proven how to blow it even with a product. It’s apathy. This company doesn’t do earnings calls, which tells you all you need to know. They are a shell for GSk to avoid taking on the development risk. David worked for GSK. All the credentials of these people are fairly subordinate- look at their LinkedIn profiles. A docile subpar management. I’m getting out of Biotech. I’ve been following other companies and it just seems like a corrupt playground. Literally seen run-ups of 20%, followed by dramatic falls in the past few days. Luckily, I’m not invested in any of those, but I can’t help to think of the investors that bought in at the highs. Good governance would have fired the management by now. It is what it is, I guess. There seems to be 0 pressure on these people. It’s all carrot, no stick. Good luck. I hope it turns around.
2 · Reply
XZeroDelta
XZeroDelta May. 21 at 4:02 PM
$SCYX I am firmly convinced that by GSK taking its time to talk to the FDA regarding the re-initiation of mass production of batches of ibrexafungerp, that it is not letting this stock run based on the fact that even Hansoh phamaceuticals has not started selling ibrexafungerp in the Chinese market yet despite having it approved for comercialization by the NMPA. Probably the reason why is because Hansoh is expecting GSK to produce the ibrexafungerp tablets so that they (Hansoh) can then sell it in the Chinese market to the tertiary hospitals and direct-to-patient pharmacies. Scynexis is being forced to survive by any means necessary, and yet they have institutional and private credit backing them up. The CEO has also bought shares in the open market. This is the time to continue to load up if you continue to believe in the long term thesis. Good luck my fellow Scynexis Longs!
1 · Reply
WhomCares
WhomCares May. 21 at 3:34 PM
$SCYX this company turned out to be the biggest turd. With an approved drug, and then some complete b******* taking it off the market because of some questionable stuff that was probably unnecessary. What a disaster. Definitely some shenanigans going on with management and GKS
0 · Reply
pantarei
pantarei May. 21 at 11:56 AM
0 · Reply
showmethemoney75
showmethemoney75 May. 20 at 12:22 PM
$SCYX This management team holds all the blame to where we are now. Should be a billion dollar company potentially but it appears they will be having their 2nd RS. They have destroyed shareholders. A company that has multiple RS is a huge red flag for most investors How these guys still have a job while stealing investors money is beyond me…. Couldn’t run a lemonade stand…
1 · Reply
pantarei
pantarei May. 20 at 10:45 AM
0 · Reply
ViktorSinclair
ViktorSinclair May. 20 at 6:51 AM
0 · Reply
morganforrest
morganforrest May. 19 at 6:04 PM
$SCYX Reverse splits are meaningless...archaic restriction based on physical newspapers...
1 · Reply
SnapCrackleStop
SnapCrackleStop May. 19 at 3:58 PM
$SCYX RS doesn’t change to value of the Company. $$$
1 · Reply
HJRaph
HJRaph May. 19 at 3:29 PM
$SCYX https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3347856:0-scyx-shareholders-approved-a-reverse-stock-split-and-reduction-of-authorized-shares/
1 · Reply
showmethemoney75
showmethemoney75 May. 19 at 3:23 PM
$SCYX Looks like the RS was voted on and passed today.. Approved either a 1 for 5 or 1 for 10. Will take place prior to 6/15 Special meeting was held today to approve
1 · Reply
showmethemoney75
showmethemoney75 May. 19 at 3:20 PM
$SCYX Dude that article is over a year old …..
1 · Reply